
A Prolonged Response and Characteristics of Trabectedin Treatment of Metastatic Soft Tissue Sarcoma
Author(s) -
Daniel Y. Reuben
Publication year - 2021
Publication title -
journal of medical cases
Language(s) - English
Resource type - Journals
eISSN - 1923-4163
pISSN - 1923-4155
DOI - 10.14740/jmc3655
Subject(s) - trabectedin , medicine , soft tissue sarcoma , sarcoma , oncology , cancer research , pathology
Unique features and treatment effects of trabectedin are presented in consideration of soft tissue sarcoma management. A prolonged time on trabectedin through 59 cycles is shown. This is one of the longer reported uses of trabectedin successfully to control disease. Adjunctive cytoreduction options with surgery, radiation or ablation are presented. Future studies would be helpful to investigate treatment holidays, the impact of multi-modality care and assessment of genetics of clonal metastases. This may assist in guiding and selecting patients for priority treatment with trabectedin.